Trending Insights
Frequently Asked Questions
-
What value is the global transdermal patch market expected to reach by 2032?
The global transdermal patch market is expected to reach a readjusted size of USD 10.05 million by 2032.
-
What CAGR is the transdermal patch market expected to exhibit by 2032?
The transdermal patch market is expected to exhibit a CAGR of 3.6% by 2032.
-
What are the driving factors of the transdermal patch market?
The driving factors of transdermal patch market include the increasing prevalence of chronic diseases and the rising awareness of the benefits of these patches.
-
Which are the key players or most dominant companies functioning in the transdermal patch market?
The dominant companies in the transdermal patch market are Hisamitsu Pharmaceutical, Johnson & Johnson, Novartis, UCB Pharma, Mylan, Teva Pharmaceutical, Nitto Denko, Grünenthal, IBSA Group, GSK, Luye Pharma Group, Pfizer, Chattem, and Dr Reddy’s Laboratories.